Inovio Pharmaceuticals, Inc. (NASDAQ:INO)’s share price traded down 5.6% during trading on Tuesday . The company traded as low as $4.22 and last traded at $4.25. 2,036,886 shares traded hands during mid-day trading, an increase of 61% from the average session volume of 1,267,421 shares. The stock had previously closed at $4.50.

A number of equities analysts have recently commented on the stock. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 28th. Zacks Investment Research lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. ValuEngine lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. BidaskClub lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 27th. Finally, Royal Bank of Canada started coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They issued an “outperform” rating and a $11.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $19.16.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The company had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. Inovio Pharmaceuticals’s revenue for the quarter was down 79.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. equities analysts expect that Inovio Pharmaceuticals, Inc. will post -1.12 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in INO. Virginia Retirement Systems ET AL purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $101,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter worth about $107,000. Neuberger Berman Group LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $115,000. Engineers Gate Manager LP purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $117,000. Finally, Emerald Advisers Inc. PA boosted its position in shares of Inovio Pharmaceuticals by 84.0% in the 3rd quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 9,280 shares in the last quarter. Institutional investors and hedge funds own 32.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Inovio Pharmaceuticals (INO) Shares Down 5.6%” was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/inovio-pharmaceuticals-ino-shares-down-5-6/1763167.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.